Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRTNASDAQ:JYNTNASDAQ:PRLDNASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.61-4.4%$0.66$0.51▼$1.80$58.55M0.32689,368 shs254,125 shsJYNTJoint$9.98-5.2%$10.89$9.58▼$17.82$152.92M1.5454,721 shs73,047 shsPRLDPrelude Therapeutics$0.78-4.5%$0.76$0.61▼$6.80$35.66M1.3269,885 shs76,739 shsSGMOSangamo Therapeutics$0.70-2.8%$0.78$0.30▼$3.18$160.44M1.468.64 million shs2.89 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio0.00%-5.91%+1.38%-23.73%-42.06%JYNTJoint0.00%-4.86%+0.40%-12.38%-37.35%PRLDPrelude Therapeutics0.00%-11.99%+21.69%-22.67%-78.25%SGMOSangamo Therapeutics0.00%-3.89%-3.29%-39.13%+39.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASRTAssertio1.6028 of 5 stars3.50.00.00.01.80.81.3JYNTJoint3.1744 of 5 stars3.52.00.00.01.93.31.9PRLDPrelude Therapeutics3.0999 of 5 stars3.22.00.00.03.35.00.6SGMOSangamo Therapeutics1.6226 of 5 stars3.31.00.00.02.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 3.00Buy$2.75349.86% UpsideJYNTJoint 3.00Buy$15.5055.31% UpsidePRLDPrelude Therapeutics 2.33Hold$4.00412.16% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$5.17638.10% UpsideCurrent Analyst Ratings BreakdownLatest JYNT, ASRT, PRLD, and SGMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025JYNTJointLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $16.005/5/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/29/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.004/8/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/7/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.503/18/2025SGMOSangamo TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$2.00 ➝ $2.003/14/2025ASRTAssertioIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$1.75(Data available from 5/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$124.96M0.47$0.55 per share1.12$1.46 per share0.42JYNTJoint$51.90M2.95$0.64 per share15.65$1.68 per share5.94PRLDPrelude Therapeutics$7M4.87N/AN/A$4.32 per share0.18SGMOSangamo Therapeutics$57.80M2.78$0.02 per share30.42$0.47 per share1.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$331.94M-$0.23N/A20.383.25-54.46%3.79%1.81%5/12/2025 (Estimated)JYNTJoint-$9.75M-$0.57N/A18.83N/A-13.95%8.24%2.33%N/APRLDPrelude Therapeutics-$121.83M-$1.69N/AN/AN/AN/A-66.89%-55.59%N/ASGMOSangamo Therapeutics-$257.83M-$0.52N/AN/AN/A-257.87%-264.16%-107.24%N/ALatest JYNT, ASRT, PRLD, and SGMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ASRTAssertio-$0.03N/AN/AN/A$27.52 millionN/A5/8/2025Q1 2025JYNTJoint-$0.02-$0.03-$0.01$0.06$13.02 million$13.08 million5/6/2025Q1 2025PRLDPrelude Therapeutics-$0.47-$0.42+$0.05-$0.42N/AN/A3/17/2025Q4 2024SGMOSangamo Therapeutics-$0.09-$0.11-$0.02-$0.11$11.70 million$7.55 million3/10/2025Q4 2024PRLDPrelude Therapeutics-$0.49-$0.38+$0.11-$0.38N/A$4.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/AJYNTJointN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.302.011.57JYNTJointN/A1.441.44PRLDPrelude TherapeuticsN/A7.047.04SGMOSangamo TherapeuticsN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%JYNTJoint76.88%PRLDPrelude Therapeutics79.72%SGMOSangamo Therapeutics56.93%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%JYNTJoint27.90%PRLDPrelude Therapeutics62.80%SGMOSangamo Therapeutics2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2095.77 million92.42 millionOptionableJYNTJoint32015.32 million10.46 millionOptionablePRLDPrelude Therapeutics12043.61 million20.47 millionOptionableSGMOSangamo Therapeutics480229.19 million202.81 millionOptionableJYNT, ASRT, PRLD, and SGMO HeadlinesRecent News About These CompaniesWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 5.70%May 10 at 1:49 AM | aaii.comSchonfeld Strategic Advisors LLC Purchases Shares of 1,709,615 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)May 8 at 4:38 AM | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $5.17 Average Price Target from AnalystsMay 8 at 1:05 AM | americanbankingnews.comSangamo Therapeutics Sets Sights on 2026 BLA Filing for Fabry Disease Gene TherapyMay 7, 2025 | precisionmedicineonline.comSangamo Therapeutics (SGMO) Projected to Post Quarterly Earnings on ThursdayMay 7, 2025 | americanbankingnews.comMarshall Wace LLP Has $344,000 Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)May 7, 2025 | marketbeat.comSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry DiseaseMay 7, 2025 | finance.yahoo.comSangamo Therapeutics Announces First Quarter 2025 Earnings CallMay 6, 2025 | businesswire.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 6, 2025 | marketbeat.com740,000 Shares in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Acquired by Acuta Capital Partners LLCMay 4, 2025 | marketbeat.comBoothbay Fund Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)May 3, 2025 | marketbeat.comSangamo Therapeutics (SGMO) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comSangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 1, 2025 | zacks.comSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)April 28, 2025 | businesswire.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Renaissance Technologies LLCApril 26, 2025 | marketbeat.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 10.12%April 21, 2025 | aaii.comWasatch Advisors LP Decreases Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)April 19, 2025 | marketbeat.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Down 5.89%April 18, 2025 | aaii.comQ1 EPS Forecast for Sangamo Therapeutics Raised by AnalystApril 12, 2025 | marketbeat.comResearch Analysts Set Expectations for SGMO Q4 EarningsApril 11, 2025 | marketbeat.comLilly, Sangamo Enter Capsid License AgreementApril 8, 2025 | contractpharma.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJYNT, ASRT, PRLD, and SGMO Company DescriptionsAssertio NASDAQ:ASRT$0.61 -0.03 (-4.39%) As of 05/9/2025 03:58 PM EasternAssertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Joint NASDAQ:JYNT$9.98 -0.55 (-5.22%) As of 05/9/2025 03:59 PM EasternThe Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.Prelude Therapeutics NASDAQ:PRLD$0.78 -0.04 (-4.49%) As of 05/9/2025 04:00 PM EasternPrelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Sangamo Therapeutics NASDAQ:SGMO$0.70 -0.02 (-2.75%) As of 05/9/2025 04:00 PM EasternSangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock Constellation Powers Up With Reinforced AI Data Center Strategy GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
